Post by Nadica (She/Her) on Sept 25, 2024 0:08:41 GMT
Human challenge study reveals lasting cognitive decline after mild COVID-19 - Published Sept 23, 2024
By Dr. Chinta Sidharthan
Unvaccinated volunteers who contracted COVID-19 in a human challenge study showed significant memory and executive function decline lasting up to a year, despite no reported subjective symptoms, prompting new questions about the virus’s long-term cognitive effects.
In a recent study published in the journal EClinicalMedicine, a team of researchers from the United Kingdom examined the cognitive deficits associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. They conducted the first human challenge study among a prospectively controlled group of unvaccinated SARS-CoV-2 naive volunteers, who were inoculated with the wild-type strain and observed for long-term cognitive problems.
Background
Substantial research now indicates that long-lasting cognitive deficits impacting memory, comprehension, and concentration occur even after mild coronavirus disease 2019 (COVID-19) cases. A large proportion of individuals who recover from COVID-19 continue to experience “brain fog,” memory lapses, and difficulty forming words for months after the initial acute infection.
Cross-sectional and longitudinal studies have observed cognitive decline in patients one year after the infection, and brain scans have detected shrinkage in areas of the brain related to cognition and memory. Furthermore, blood tests in patients hospitalized due to SARS-CoV-2 infections have detected elevated levels of brain injury markers, such as neurofilament light (NfL) and glial fibrillary acidic protein (GFAP), indicative of potential future cognitive problems, though markers like Tau were not significantly different between infected and uninfected groups.
However, the retrospective nature of these studies has posed difficulties in accounting for the role of occupations, pre-existing health conditions, and social factors in the risk of cognitive deficits after COVID-19. Furthermore, the pace at which cognitive deficits develop after mild SARS-CoV-2 infections and the duration of these deficits remains unclear.
About the study
In the present study, the researchers challenged a group of unvaccinated, SARS-CoV-2 naive volunteers with the wild-type strain of the virus in controlled conditions. The volunteers were then quarantined and followed up to determine the long-term cognitive impacts of COVID-19.
The researchers ensured that all the ethical guidelines were followed in this human challenge study, and written consent was obtained from all the volunteers, who were also compensated for the time spent in quarantine.
The study enrolled 36 healthy adults between 18 and 30 years who had never been vaccinated against or infected with SARS-CoV-2. Of these, 18 participants were classified as infected, while 16 were uninfected. The volunteers underwent extensive tests and screening, including blood tests, chest radiography, body mass index, and assessments for COVID-19 risk factors.
The participants were then intranasally inoculated with SARS-CoV-2 and quarantined for at least two weeks. The follow-ups occurred at non-regular intervals for up to a year after the inoculation.
The viral loads in all the infected participants were monitored twice a day through naso- and oropharyngeal swabs. Additionally, the researchers administered a subjective symptom survey thrice daily to track the symptoms. The participants were categorized based on whether they experienced a sustained viral infection, and six were administered remdesivir as a precaution.
The researchers measured the participants' cognitive performance through 11 computer-based tasks that measured various cognitive domains, such as reaction time, memory, spatial reasoning, and planning. The participants were required to perform these tasks at baseline, on each day of the quarantine, and at each of the five follow-ups. The primary cognitive measure was the baseline-corrected global cognitive composite score or bcGCCS.
Additionally, the researchers also analyzed the levels of brain injury markers, such as neurofilament light (NfL) and glial fibrillary acidic protein (GFAP), in the blood samples obtained from the participants.
Results
The study found that bcGCCS scores indicated that the infected individuals exhibited significant cognitive deficits compared to the uninfected individuals. These deficits were sustained for almost a year, with no recovery or improvements noted. Despite these objective cognitive deficits, none of the infected volunteers reported subjective cognitive symptoms.
The cognitive area that showed the largest deficit was memory-related tasks, such as those measuring immediate and delayed memory recall. The infected individuals performed worse than the uninfected ones on memory-related and executive planning tasks.
The cognitive tasks were grouped based on whether learning effects were observed across sessions, and the results indicated that the cognitive differences between the uninfected and infected individuals were robust even after accounting for learning effects.
Furthermore, some brain injury biomarkers in the serum, such as GFAP, were higher in the infected participants than in the uninfected ones, but other markers, such as Tau and NfL, were not significantly different between the two groups.
Although these findings indicated that SARS-CoV-2 infections resulted in measurable differences in various aspects of cognitive decline, especially in the areas of memory and executive function, the statistical tests revealed no significant correlation between cognitive deficits and viral load, brain markers, and symptom severity.
Conclusions
The study indicated that while objective and measurable changes could be observed in various aspects of cognitive performance due to SARS-CoV-2 infections, further research is essential to understand the biological mechanisms behind these cognitive deficits. The researchers believe that more long-term studies on larger cohorts are required to understand the long-term impact of COVID-19. Importantly, the study results suggest that these cognitive changes might persist even in the absence of subjective symptoms, highlighting the need for more sensitive assessment tools.
Journal reference:
Trender, W., Hellyer, P. J., Killingley, B., Kalinova, M., Mann, A. J., Catchpole, A. P., Menon, D., Needham, E., Thwaites, R., Chiu, C., Scott, G., & Hampshire, A. (2024). Changes in memory and cognition during the SARS-CoV-2 human challenge study. EClinicalMedicine, 76. DOI:10.1016/j.eclinm.2024.102842, www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00421-8/fulltext
Study Link: www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00421-8/fulltext
By Dr. Chinta Sidharthan
Unvaccinated volunteers who contracted COVID-19 in a human challenge study showed significant memory and executive function decline lasting up to a year, despite no reported subjective symptoms, prompting new questions about the virus’s long-term cognitive effects.
In a recent study published in the journal EClinicalMedicine, a team of researchers from the United Kingdom examined the cognitive deficits associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. They conducted the first human challenge study among a prospectively controlled group of unvaccinated SARS-CoV-2 naive volunteers, who were inoculated with the wild-type strain and observed for long-term cognitive problems.
Background
Substantial research now indicates that long-lasting cognitive deficits impacting memory, comprehension, and concentration occur even after mild coronavirus disease 2019 (COVID-19) cases. A large proportion of individuals who recover from COVID-19 continue to experience “brain fog,” memory lapses, and difficulty forming words for months after the initial acute infection.
Cross-sectional and longitudinal studies have observed cognitive decline in patients one year after the infection, and brain scans have detected shrinkage in areas of the brain related to cognition and memory. Furthermore, blood tests in patients hospitalized due to SARS-CoV-2 infections have detected elevated levels of brain injury markers, such as neurofilament light (NfL) and glial fibrillary acidic protein (GFAP), indicative of potential future cognitive problems, though markers like Tau were not significantly different between infected and uninfected groups.
However, the retrospective nature of these studies has posed difficulties in accounting for the role of occupations, pre-existing health conditions, and social factors in the risk of cognitive deficits after COVID-19. Furthermore, the pace at which cognitive deficits develop after mild SARS-CoV-2 infections and the duration of these deficits remains unclear.
About the study
In the present study, the researchers challenged a group of unvaccinated, SARS-CoV-2 naive volunteers with the wild-type strain of the virus in controlled conditions. The volunteers were then quarantined and followed up to determine the long-term cognitive impacts of COVID-19.
The researchers ensured that all the ethical guidelines were followed in this human challenge study, and written consent was obtained from all the volunteers, who were also compensated for the time spent in quarantine.
The study enrolled 36 healthy adults between 18 and 30 years who had never been vaccinated against or infected with SARS-CoV-2. Of these, 18 participants were classified as infected, while 16 were uninfected. The volunteers underwent extensive tests and screening, including blood tests, chest radiography, body mass index, and assessments for COVID-19 risk factors.
The participants were then intranasally inoculated with SARS-CoV-2 and quarantined for at least two weeks. The follow-ups occurred at non-regular intervals for up to a year after the inoculation.
The viral loads in all the infected participants were monitored twice a day through naso- and oropharyngeal swabs. Additionally, the researchers administered a subjective symptom survey thrice daily to track the symptoms. The participants were categorized based on whether they experienced a sustained viral infection, and six were administered remdesivir as a precaution.
The researchers measured the participants' cognitive performance through 11 computer-based tasks that measured various cognitive domains, such as reaction time, memory, spatial reasoning, and planning. The participants were required to perform these tasks at baseline, on each day of the quarantine, and at each of the five follow-ups. The primary cognitive measure was the baseline-corrected global cognitive composite score or bcGCCS.
Additionally, the researchers also analyzed the levels of brain injury markers, such as neurofilament light (NfL) and glial fibrillary acidic protein (GFAP), in the blood samples obtained from the participants.
Results
The study found that bcGCCS scores indicated that the infected individuals exhibited significant cognitive deficits compared to the uninfected individuals. These deficits were sustained for almost a year, with no recovery or improvements noted. Despite these objective cognitive deficits, none of the infected volunteers reported subjective cognitive symptoms.
The cognitive area that showed the largest deficit was memory-related tasks, such as those measuring immediate and delayed memory recall. The infected individuals performed worse than the uninfected ones on memory-related and executive planning tasks.
The cognitive tasks were grouped based on whether learning effects were observed across sessions, and the results indicated that the cognitive differences between the uninfected and infected individuals were robust even after accounting for learning effects.
Furthermore, some brain injury biomarkers in the serum, such as GFAP, were higher in the infected participants than in the uninfected ones, but other markers, such as Tau and NfL, were not significantly different between the two groups.
Although these findings indicated that SARS-CoV-2 infections resulted in measurable differences in various aspects of cognitive decline, especially in the areas of memory and executive function, the statistical tests revealed no significant correlation between cognitive deficits and viral load, brain markers, and symptom severity.
Conclusions
The study indicated that while objective and measurable changes could be observed in various aspects of cognitive performance due to SARS-CoV-2 infections, further research is essential to understand the biological mechanisms behind these cognitive deficits. The researchers believe that more long-term studies on larger cohorts are required to understand the long-term impact of COVID-19. Importantly, the study results suggest that these cognitive changes might persist even in the absence of subjective symptoms, highlighting the need for more sensitive assessment tools.
Journal reference:
Trender, W., Hellyer, P. J., Killingley, B., Kalinova, M., Mann, A. J., Catchpole, A. P., Menon, D., Needham, E., Thwaites, R., Chiu, C., Scott, G., & Hampshire, A. (2024). Changes in memory and cognition during the SARS-CoV-2 human challenge study. EClinicalMedicine, 76. DOI:10.1016/j.eclinm.2024.102842, www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00421-8/fulltext
Study Link: www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00421-8/fulltext